Pinsent Masons advises 4D Pharma PLC on innovative move to NASDAQ

28 Oct 2020 | 10:31 am | 1 min. read

Multinational law firm Pinsent Masons has advised AIM listed biotech company 4D Pharma plc (4D) on its acquisition of Longevity Acquisition Corporation, a special-purpose acquisition company (SPAC) listed on NASDAQ. Upon completion of the transaction 4D will apply for its American Depositary Shares to be admitted to trading on NASDAQ.

4D, who are leading the development of live biotherapeutic products, are believed to be the first UK biotech to make the move to NASDAQ via the acquisition of a SPAC, breaking new ground for UK listed biotechs. The Company will also maintain its current listing on AIM.

With 4D acquiring the SPAC in order to inherit its listing on NASDAQ, they are able to by-pass the usual nine month lead-in time foreign issuers have to contend with when seeking a direct listing on NASDAQ.

The Pinsent Masons team was led by Charles Waddell and Sunjay Malhotra with assistance from Julian Stanier, Amy Moore and Nathalie Goetsches; US securities advice was provided by Roberta Markovina and Beatrice Kelly; Eloise Walker, Jamie Robson and Daniel Place assisted on UK tax matters; and Fleur Benns and James Sullivan-Tailyour provided assistance with regards to 4D’s share option plans.

Commenting on the transaction, lead partner at Pinsent Masons Charles Waddell said:

"We have enjoyed working with 4D for a number of years, they are at the cutting edge of live biotherapeutic products and this transaction is an important step in their future development and access to key to international markets.

Given the number of European biotechs that covet a move to NASDAQ, and notwithstanding the complex financing structures of SPACs, this deal highlights that there is an alternative route to the US markets. It is therefore unlikely to be the last biotech we see looking at SPACs to access the deep pool of sophisticated investors in the US."

Latest press releases

Show me all press releases

Pinsent Masons wins Construction Team of the Year at the Middle East Legal Awards

Multinational law firm Pinsent Masons has won Construction Team of the Year at the Middle East Legal Awards 2021.

Pinsent Masons collaborates with LifeArc on expert paper to support drug repurposing

Multinational law firm Pinsent Masons has collaborated with medical research charity LifeArc, on a new report offering expert advice, insights and practical tips to charities, researchers and funders hoping to repurpose drugs for other – often rare and fatal – conditions.

Pinsent Masons advises UCL on £300m sustainability bond

Multinational law firm Pinsent Masons has advised University College London (UCL) on its debut issue of £300m 1.625% sustainability bonds due 2061 - the first publicly listed sustainability bonds in the higher education sector.

People who viewed this press release also viewed

Show me all press releases

Pinsent Masons collaborates with LifeArc on expert paper to support drug repurposing

Multinational law firm Pinsent Masons has collaborated with medical research charity LifeArc, on a new report offering expert advice, insights and practical tips to charities, researchers and funders hoping to repurpose drugs for other – often rare and fatal – conditions.

Pinsent Masons launches its tax practice in Spain

Multinational law firm Pinsent Masons has hired Gonzalo Gil Suarez in Madrid to lead the firm’s tax law practice in Spain.

Pinsent Masons recruits third partner in Amsterdam hiring life sciences specialist

Multinational law firm Pinsent Masons has recruited Life Sciences partner, Machteld Hiemstra in Amsterdam as it develops its Netherlands-based technology, science and industry (TSI) capabilities.

For all media enquiries, including arranging an interview with one of our spokespeople, please contact the press office on

+44 (0)20 7418 8199 or 

Location contacts